Literature DB >> 20128815

The selective beta1-adrenoceptor antagonist nebivolol is a potential oestrogen receptor agonist with neuroprotective abilities.

D Manthey1, M Gamerdinger, C Behl.   

Abstract

BACKGROUND AND
PURPOSE: Nebivolol, a selective beta(1)-adrenoceptor antagonist mediating rapid vasodilating effects, is used clinically to treat hypertension. Recently, it was reported that nebivolol also acts as an oestrogen receptor (ER) agonist. To investigate the neuroprotective potential of oestrogens, we assessed the oestrogenic effects of nebivolol in several in vitro neuronal models. EXPERIMENTAL APPROACH: Human neuroepithelioma SK-N-MC cells stably transfected with human ER alpha and beta, and mouse N2A neuroblastoma cells expressing human APP695(SWE)[N2Aswe, stably transfected with the Swedish mutation form of the Alzheimer-associated amyloid precursor protein (APPswe, K670M/N671L)] were incubated with different concentrations of nebivolol and 17beta-oestradiol (E2) for 24-48 h. ER activation was detected in a specific reporter assay, and ER-dependent gene expression was measured by quantitative real-time PCR (qRT PCR). Furthermore, cell survival rates were determined, and oxidative stress was induced by hydrogen peroxide and paraquat. Amyloid beta protein precursor (APP) processing was investigated, and the cleavage fragments sAPPalpha and Abeta were quantified via alpha-, beta- and gamma-secretase activity assays. Alterations of secretase expression levels were determined by qRT PCR. KEY
RESULTS: Nebivolol induces oestrogen-dependent gene transcription, and protects neuronal cells against oxidative stress even at low and physiological concentrations (10(-8) M). Moreover, nebivolol modulates processing of APP in mouse neuronal N2Aswe cells by increasing alpha-secretase activity, ultimately leading to enhanced release of soluble non-amyloidogenic sAPPalpha. CONCLUSIONS AND IMPLICATIONS: We showed that nebivolol acts as ER agonist in neuronal cell lines, and suggest oestrogen-like neuroprotective effects mediated by nebivolol.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20128815      PMCID: PMC2848930          DOI: 10.1111/j.1476-5381.2009.00610.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  50 in total

1.  The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties.

Authors:  B Moosmann; C Behl
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

2.  Estrogen can act via estrogen receptor alpha and beta to protect hippocampal neurons against global ischemia-induced cell death.

Authors:  Nora R Miller; Teresa Jover; Hillel W Cohen; R Suzanne Zukin; Anne M Etgen
Journal:  Endocrinology       Date:  2005-04-07       Impact factor: 4.736

Review 3.  Interdependence of oestrogen and insulin-like growth factor-I in the brain: potential for analysing neuroprotective mechanisms.

Authors:  Pablo Mendez; Iñigo Azcoitia; Luis Miguel Garcia-Segura
Journal:  J Endocrinol       Date:  2005-04       Impact factor: 4.286

Review 4.  From structural biochemistry to expression profiling: neuroprotective activities of estrogen.

Authors:  D Manthey; C Behl
Journal:  Neuroscience       Date:  2005-12-15       Impact factor: 3.590

5.  Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity.

Authors:  R Preston Mason; Ruslan Kubant; Robert F Jacob; Mary F Walter; Bohdan Boychuk; Tadeusz Malinski
Journal:  J Cardiovasc Pharmacol       Date:  2006-07       Impact factor: 3.105

6.  Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells.

Authors:  Edmund C Chang; Jonna Frasor; Barry Komm; Benita S Katzenellenbogen
Journal:  Endocrinology       Date:  2006-06-29       Impact factor: 4.736

Review 7.  Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: Insights from basic science and clinical studies.

Authors:  Judith L Turgeon; Molly C Carr; Pauline M Maki; Michael E Mendelsohn; Phyllis M Wise
Journal:  Endocr Rev       Date:  2006-06-09       Impact factor: 19.871

8.  Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides.

Authors:  H Xu; G K Gouras; J P Greenfield; B Vincent; J Naslund; L Mazzarelli; G Fried; J N Jovanovic; M Seeger; N R Relkin; F Liao; F Checler; J D Buxbaum; B T Chait; G Thinakaran; S S Sisodia; R Wang; P Greengard; S Gandy
Journal:  Nat Med       Date:  1998-04       Impact factor: 53.440

Review 9.  Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application.

Authors:  Claus Pietrzik; Christian Behl
Journal:  Int J Exp Pathol       Date:  2005-06       Impact factor: 1.925

10.  Alpha and beta estradiol protect neuronal but not native PC12 cells from paraquat-induced oxidative stress.

Authors:  Sylvie Gélinas; Geneviève Bureau; Barbara Valastro; Guy Massicotte; Francesca Cicchetti; Keith Chiasson; Benoît Gagne; Julie Blanchet; Maria-Grazia Martinoli
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

View more
  3 in total

1.  In silico identification and pharmacological evaluation of novel endocrine disrupting chemicals that act via the ligand-binding domain of the estrogen receptor α.

Authors:  Fiona M McRobb; Irina Kufareva; Ruben Abagyan
Journal:  Toxicol Sci       Date:  2014-06-13       Impact factor: 4.849

2.  Cell Models for the Study of Sex Steroid Hormone Neurobiology.

Authors:  Chang Su; Nataliya Rybalchenko; Derek A Schreihofer; Meharvan Singh; Babak Abbassi; Rebecca L Cunningham
Journal:  J Steroids Horm Sci       Date:  2012

3.  Estrogen receptor α regulates non-canonical autophagy that provides stress resistance to neuroblastoma and breast cancer cells and involves BAG3 function.

Authors:  V Felzen; C Hiebel; I Koziollek-Drechsler; S Reißig; U Wolfrum; D Kögel; C Brandts; C Behl; T Morawe
Journal:  Cell Death Dis       Date:  2015-07-09       Impact factor: 8.469

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.